Opus Genetics, Inc. (IRD): R&D Expense
$30.81M
Year ended 2025-12-31
$38.62M
Trailing 12 months to 2026-06-30
+29.0%
3-year compound annual growth
+35.9%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $30.81M | +14.8% | 2026-03-12, From 2025-01-01 |
| 2024-12-31 | $26.85M | +52.1% | 2026-03-12, From 2024-01-01 |
| 2023-12-31 | $17.65M | +23.0% | 2025-03-31, From 2023-01-01 |
| 2022-12-31 | $14.36M | -5.4% | 2024-03-08, From 2022-01-01 |
| 2021-12-31 | $15.17M | +128.2% | 2023-03-30, From 2021-01-01 |
| 2020-12-31 | $6.65M | +180.2% | 2022-03-24, From 2020-01-01 |
| 2019-12-31 | $2.37M | n/a | 2021-03-11, From 2019-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Opus Genetics, Inc. (IRD) | 2025-12-31 | $30.81M | +14.8% |
| Arbutus Biopharma Corp (ABUS) | 2025-12-31 | $25.24M | -53.3% |
| Pyxis Oncology, Inc. (PYXS) | 2025-12-31 | $73.70M | +25.4% |
| CV Sciences, Inc. (CVSI) | 2025-12-31 | $122.0K | +3.4% |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | 2025-12-31 | $44.49M | +11.3% |
| Evommune, Inc. (EVMN) | 2025-12-31 | $74.04M | +15.3% |
| uniQure N.V. (QURE) | 2025-12-31 | $140.67M | -2.2% |
| Emmaus Life Sciences, Inc. (EMMA) | 2025-12-31 | $313.0K | -52.4% |
| Prelude Therapeutics Inc (PRLD) | 2025-12-31 | $94.30M | -20.1% |
Compare IRD, ABUS, PYXS, CVSI side by side · Screen every company in Pharmaceutical Preparations ↗